Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Jun. 28, 2019 |
Mar. 31, 2020 |
Mar. 31, 2019 |
Dec. 31, 2019 |
|
Significant Accounting Policies [Line Items] | ||||
Reverse stock split | 1-for-14 | |||
Accumulated deficit | $ 320,551 | $ 322,304 | ||
Cash, cash equivalents and available-for-sale investments | $ 49,800 | |||
Shares used in computing diluted net income (loss) per share | 6,884,797 | 2,418,674 | ||
Restricted Stock Units [Member] | ||||
Significant Accounting Policies [Line Items] | ||||
Shares used in computing diluted net income (loss) per share | 3,006 | |||
Pangu BioPharma [Member] | Hong Kong [Member] | ||||
Significant Accounting Policies [Line Items] | ||||
Majority-owned subsidiary percentage | 98.00% |